Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (K23AI125715)
Received: 19 July 2022
Accepted: 13 September 2022
First Online: 28 October 2022
: This study deemed exempt by the Johns Hopkins Institutional Review Board (IRB00104750). No consent was obtained for individual study participants by the study authors as this was a secondary data analysis and only de-identified data from the NSQIP dataset were used. All methods were carried out in accordance with the relevant guidelines and regulations.
: Not Applicable.
: ST has been a consultant for Biofire Diagnostics, Roche Molecular Diagnostics and Luca Biologics, receives royalties from UPTODATE and has received speaker honoraria from Roche Molecular Diagnostics and Medscape/WebMD. EW co-owns Celeflux LLC, a start-up medical device company.